Poster Presentation ESA-SRB-APEG-NZSE 2022

Real world data of the Control IQ system in a paediatric population in a single Paediatric Diabetes Centre. (#293)

Ailsa Marshall 1 , Lena Lim 1 , Shihab Hameed 1 2 3 4 , Kim Ramjan 1 2 5 , Amy Wanaguru 1 , Monique Stone 1 , Nghi Bui 1 , Allyson MacDonald 1 6 , Ohn Nyunt 1 2 3 4
  1. Royal North Shore Hospital, Sydney, NSW, Australia
  2. Northern Clinical school, University of Sydney, Sydney, NSW, Australia
  3. School of women's and children's health, University of New South Wales, Sydney, NSW, Australia
  4. Paediatric Endocrinology Department, Sydney Children's Hospital, Randwick, NSW, Australia
  5. School of Medicine, Western Sydney University, Sydney, NSW, Australia
  6. Paediatric Oncology Department, Children's Hospital Westmead, Westmead, NSW, Australia

 

Diabetes technologies are evolving rapidly. Automated insulin delivery systems are designed to improve diabetes management and there is emerging data on their efficacy in the real world paediatric population. We aimed to assess the efficacy of the Control IQ™ (CIQ) system following commencement in our Paediatric Diabetes clinic. We included all patients with type 1 diabetes mellitus from our clinic on Tandem® t:Slim X2™ pump with Dexcom® G6 sensor using sensor > 70% of the time who commenced CIQ (n=3 early release program 18th March and n= 37 following national launch 15th April 2022 to 12th August 2022). Pump uploads were completed and analysed through glooko/diasend® to compare two weeks of data at baseline, 2 weeks, 6 weeks, 3 months and 6 months post-commencement of CIQ for average sensor glucose (Av SG), coefficient of variation (CV), time in range  (TIR: 3.9 to 10mmol/L), time below range (TBR:<3.9mmol/L), time above range (TAR: 10.1mmol/L to 13.9mmol/L), Very high > 13.9mmol/L and total daily insulin dose. SPSS was used for statistical analysis for ANOVA to compare the variables at different time points (p<0.05 was considered as statistically significant). We analysed a total of 40 patients, 35 have been using CIQ for 6 weeks and 28 for 3 months. The results are reported in the table 1. In our real world data, we found that percent TIR increased, Av SG, TAR >10.1mmol/L and Very high >13.9mmol/L decreased at 3 months of CIQ. We plan to continue gathering data prospectively. 

62ff0323aec71-Table+1+APEG.jpg